Company Filing History:
Years Active: 1988-1994
Title: Innovator Spotlight: Masahiro Maki from Akita, Japan
Introduction
Masahiro Maki is a renowned inventor based in Akita, Japan. He holds a commendable portfolio with two notable patents to his name. His work primarily focuses on advancements in biomedicine, particularly involving human placenta-derived substances.
Latest Patents
Masahiro Maki's latest patents showcase his innovative contributions to medical science. The first patent is titled "Placenta-derived coagulation inhibitor." This invention discloses a monoclonal antibody specific to a human placenta-derived coagulation inhibitor. The antibody is produced by culturing a hybridoma that secretes it. Furthermore, the human placenta-derived coagulation inhibitor can be purified using the monoclonal antibody as an immunoadsorbent, and it can also be immunologically assayed through these antibodies.
His second patent, "Placenta-derived anticoagulating substance, process for preparing same," outlines novel human placenta-derived anticoagulating substances that possess unique properties, which could have significant implications in the medical field.
Career Highlights
Masahiro Maki is associated with Kowa Company Limited, where he continues to push the boundaries of innovation in biopharmaceuticals. His work has garnered attention in various scientific circles, proving his capabilities as an inventor in a highly competitive industry.
Collaborations
Masahiro's journey is supported by collaborations with talented coworkers, such as Hideo Tani and Hiroshi Nakao. Together, they contribute to the innovative environment at Kowa Company Limited, fostering breakthroughs in research and development.
Conclusion
With a focus on the development of placenta-derived biomedical substances, Masahiro Maki exemplifies the spirit of innovation. His contributions to the field of medicine through his patents reflect a commitment to improving healthcare solutions. As he continues to explore new frontiers in biomedicine, his work holds the promise of significant advancements in treatment options for patients worldwide.